Prognostic significance of EBMT score system for hematological malignancies with allogeneic hematopoietic stem cell transplantation / 中华血液学杂志
Chinese Journal of Hematology
; (12): 655-658, 2013.
Article
em Zh
| WPRIM
| ID: wpr-272143
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the impact of EBMT score system in patients with hematological malignancies received allogeneic hematopoietic stem cell transplantation (allo-HSCT).</p><p><b>METHODS</b>A total of 144 consecutive patients were analyzed retrospectively. According to the EBMT score system, including age, disease status before transplantation, interval between diagnoses to transplantation, donor/recipient sex match and donor type, patients were divided into 3 risk groups: low risk (score 0-1), intermediate risk (score 2-3) and high risk (score 4-7).</p><p><b>RESULTS</b>The median follow-up duration were 413 (10-1827) days for all patients and 837 (166-1827) days for alive patients. The estimated 4-year overall survival (OS), transplant-related mortality (TRM) and relapse rate (RR) were (57.5±4.6)%, (21.6±3.7)% and (42.7±6.1)%, respectively. The 4-year OS, TRM and RR were (72.2±9.0)%, (8.1±4.5)% and (27.3±8.7)% in the low-risk group, significantly superior to both intermediate-risk group [(57.7±6.0)%, (23.1±5.1)% and (44.9±8.3)%] and high-risk group [(36.9±10.2)%, (33.5±9.2)% and (51.5±11.8)%] (P<0.01, 0.02 and 0.009 for OS, TRM and RR respectively).</p><p><b>CONCLUSION</b>The EBMT score system provides prognostic significance for OS, TRM and RR in patients with hematological malignancies received allo-HSCT.</p>
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Prognóstico
/
Terapêutica
/
Transplante Homólogo
/
Estudos Retrospectivos
/
Resultado do Tratamento
/
Transplante de Células-Tronco Hematopoéticas
/
Neoplasias Hematológicas
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Chinese Journal of Hematology
Ano de publicação:
2013
Tipo de documento:
Article